---
title: "aTyr Pharma submits FDA protocol for planned Phase 3 efzofitimod sarcoidosis study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292763348.md"
description: "aTyr Pharma submitted a protocol to the US FDA in June 2026 for a planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. The primary endpoint is forced vital capacity, with the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint."
datetime: "2026-07-15T12:02:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292763348.md)
  - [en](https://longbridge.com/en/news/292763348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292763348.md)
generator: "portal-rs"
---

# aTyr Pharma submits FDA protocol for planned Phase 3 efzofitimod sarcoidosis study

-   aTyr Pharma submitted a protocol to the US FDA in June 2026 for a planned Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease. \* The company plans to use forced vital capacity as the primary endpoint, with the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9762427) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [aTyr Pharma submits Phase 3 efzofitimod trial protocol to FDA for pulmonary sarcoidosis study](https://longbridge.com/en/news/295273060.md)
- [Commerce Bank Makes New Investment in Quest Diagnostics Incorporated $DGX](https://longbridge.com/en/news/296754573.md)
- [Commerzbank Aktiengesellschaft FI Takes $1.42 Million Position in Quest Diagnostics Incorporated $DGX](https://longbridge.com/en/news/296322041.md)
- [11:25 ETILD Day 2026 Spotlights Precision Medicine's Potential to Transform Patient Care](https://longbridge.com/en/news/296512797.md)
- [M1 Capital Management LLC Invests $1.21 Million in DTE Energy Company $DTE](https://longbridge.com/en/news/296679859.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**